This study is testing a new drug called camizestrant for early breast cancer that is ER+/HER2- (meaning the cancer cells have estrogen receptors but not an excess of HER2 protein). Patients must have already had surgery and at least 2 years of hormone therapy (endocrine therapy) and are considered at risk for the cancer to come back. The study compares camizestrant with standard hormone therapy over 5 years, to see which works better.

*Key Points:*

• **Study Length:** Treatment lasts 5 years, but patients are followed for 10 years.
• **Eligibility:** Must be an adult who completed surgery and at least 2 years of hormone therapy.
• **Risks and Exclusions:** Cannot participate if you have advanced cancer, other significant health issues, or are pregnant.

Participants will help researchers learn if camizestrant is better for preventing cancer from coming back. You might be able to join if you fit the study's specific requirements, and you will be closely monitored throughout the study.